Ultrasound-guided transient elastography and two-dimensional shear wave elastography for assessment of liver fibrosis: emphasis on technical success and reliable measurements

Lee, Ji Hyuk; Kang, Hyo-Jin; Yoon, Jeong Hee; Lee, Jeong Min

doi:10.14366/usg.20036

Cited by 10 publications

(13 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 Moreover, transient elastography (Fibroscan) has been shown to yield good results in the diagnosis of various chronic liver diseases. 22 Further, it is the most commonly used and verified technique recommended by EASL as well as by the Asian Pacific Association for the Study of the APASL. 23,24 Consistent with these recommendations, the current survey findings indicate that Fibroscan was the most preferred technique in Indian clinical settings.…”

Section: Discussionmentioning

confidence: 99%

Epidemiology and treatment practices of chronic cholestatic liver disease in India: a physician survey-based study

Ravindra

Lahoti

Das³

2022

Int J Sci Rep

View full text Add to dashboard Cite

Background: Chronic cholestatic liver disease (CCLD) constitutes an intricate array of liver diseases in India. A physician-based survey was conducted to understand the prevalence, current treatment approaches, and gaps in the management of CCLD in India. Methods: A total of 215 physicians participated to complete a questionnaire comprising 35 questions related to the prevalence and current treatment of CCLD and assess gaps in its management. Results: Most physicians (53.5%) reported liver disorders with cholestasis to be prevalent in 10-20% of patients, while 34.9% reported their prevalence in 21-30% of patients. Alcoholic liver disease with cholestasis (CCLD [ALD]) was reported in 10-20% of patients and 21-30% of patients by 33.5% and 37.2% of physicians, respectively. Drug-induced liver disease with cholestasis (CCLD [DILI]) was reported to be present in 5-10% of patients by 34.9% of physicians. Ursodeoxycholic acid (UDCA) was found to be used by 60% physicians in >50% of patients with CCLD (ALD), commonly for a period of 4-12 weeks (48.4% physicians), while it was used for 12-24 weeks by 38.1% physicians in CCLD (DILI); for both conditions, the preferred dose was 10-15 mg/kg body weight. UDCA was reported to have good tolerability and efficacy by most physicians for both conditions. Conclusions: In light of scarce data on CCLD prevalence and management approaches in India, the present survey findings provide useful insights on its prevalence in India and support the use of UDCA therapy for the management of its symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiology and treatment practices of chronic cholestatic liver disease in India: a physician survey-based study

Ravindra

Lahoti

Das³

2022

Int J Sci Rep

View full text Add to dashboard Cite

show abstract

“…In addition, the different physical conformation of the rib cage, the presence of excessive fat, and the different hepatic volumes are elements that may affect the correct identification of the suitable intercostal space and the distance from the anterior or middle axillary line as points on which to lay the probe for the ten measurements [17,18]. In this regard, the use of the ultrasound probe to identify an optimal measurement point is a modality that can offer advantages [19]. The latest generation of FibroScan ® instruments have a standard ultrasound probe on board that allows the visualization of the liver segment on which to perform the measurement [20].…”

Section: Methodsmentioning

confidence: 99%

Liver Involvement in Patients With Systemic Sclerosis: Role of Transient Elastography in the Assessment of Hepatic Fibrosis and Steatosis

Cuomo¹,

Iandoli²,

Galiero³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Systemic sclerosis (SSc) is a rare, multisystemic disorder of connective tissue, characterized by widespread inflammation, vascular abnormalities, and both skin and visceral organ fibrosis. Tissue fibrosis is the final phase of a complex biological process of immune activation and vascular damage. Objectives The aim of study was to assess hepatic fibrosis and steatosis in SSc patients by transient elastography (TE). Methods Fifty-nine SSc patients, satisfying the 2013 ACR/EULAR classification criteria, were recruited. Clinical and laboratory findings, modified Rodnan skin score (mRSS), ac-tivity index, video-capillaroscopy, echocardiography, and lung function data were ana-lyzed. Liver stiffness (LS) was measured by transient elastography (TE), with 7 kPa used as the cut-off value for significant liver fibrosis and steatosis. Specifically, values ≥ 238 CAP ≤ 259 dB/m were considered consistent with mild steatosis (S1), 260 ≥ CAP ≤ 290 dB/m with moderate steatosis (S2) and ≥291 dB/m with severe steatosis (S3) Results The median age of patients was 51 years, with a median disease duration of 6 years. Median LS was 4.5 (2.9–8.3) kPa; 41 patients (69.5%) had no evidence of fibrosis (F=0), 16 (27.1%) displayed LS values between 5.2 and 7 kPa; only 2 patients (3.4%) had LS values >7 kPa (F3). The median CAP value for liver steatosis was 223 dB/m (IQR: 164–343). Overall, 39 patients (66.1%) did not show evidence of steatosis (CAP values <238 dB/m); 9 patients (15.2%) showed values consistent with mild (S1) steatosis (CAP value ≥238 ≤259 dB/m); 8 patients (13.5%) had moderate (S2) steatosis (CAP value ≥260 ≤290 dB/m); 3 patients (5.1%) were deemed to have severe steatosis (S3) due to CAP values ≥291 dB/m. Conclusions Only 3.4% of our patient population showed evidence of marked liver fibrosis, which is the same prevalence as that expected in the general population. Likewise, the prevalence of significant steatosis was low (5.1%) and depending on the same variables associated with fatty liver in the general population. TE was shown to be an easy and valuable method for detection and screening of liver fibrosis in SSc patients with no additional risk factors for liver disease.

show abstract

“…In addition, a different physical conformation of the rib cage, the presence of excessive fat, or a different hepatic volumetry are elements that may affect the point in the intercostal space, and the distance from the anterior or middle axillary line, at which to lay the probe for the 10 measurements [ 17 ]. In this regard, the use of the ultrasound probe to identify an optimal measurement point is a modality that can offer advantages [ 18 ].…”

Section: Technical Notesmentioning

confidence: 99%

Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review

Rinaldi

Giorgione

Esposito

et al. 2023

Viruses

View full text Add to dashboard Cite

Transient elastography by FibroScan® (Echosens, Paris, France) is a non-invasive method that can provide a reliable measurement of liver fibrosis through the evaluation of liver stiffness. Despite its limitations and risks, liver biopsy has thus far been the only procedure able to provide data to quantify fibrosis. Scientific evidence and clinical practice have made it possible to use FibroScan® in the diagnostic work-up of several liver diseases to monitor patients’ long-term treatment response and for complication prevention. For these reasons, this procedure is widely used in clinical practice and is still being investigated for further applications. The aim of this narrative review is to provide a comprehensive overview of the main applications of transient elastography in the current clinical practice.

show abstract

Ultrasound-guided transient elastography and two-dimensional shear wave elastography for assessment of liver fibrosis: emphasis on technical success and reliable measurements

Cited by 10 publications

References 39 publications

Epidemiology and treatment practices of chronic cholestatic liver disease in India: a physician survey-based study

Epidemiology and treatment practices of chronic cholestatic liver disease in India: a physician survey-based study

Liver Involvement in Patients With Systemic Sclerosis: Role of Transient Elastography in the Assessment of Hepatic Fibrosis and Steatosis

Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review

Contact Info

Product

Resources

About